← ANALYST RATINGS · TIPRANKS
Ginkgo Bioworks Holdings (DNA): analyst forecast and price target
Analyst consensus
Moderate Sell0 Buy1 Hold2 Sell
Ratings of 3 analysts in the last 3 months · top analysts only12-month forecast
Based on 3 price targets given in the last 3 months, the average target is $8.00, the highest $11.00, the lowest $5.00. The average is −22.1% from the last price of $10.27.
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Brendan Smith★★★★★★★★★★#458 · hits 56% · avg +27.3% | TD Cowen | $9.00 → $11.00+22.2% | Hold | +7.1% | Reiterated | 13.10.26on TipRanks 09:00 | −0.2%next day −0.9% | ↗ |
| AI xAi BiotechnologyxAI Grok-4 | TipRanks - xAI | $13.00 → $12.00−7.7% | Hold | +16.8% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI DeepSeek BiotechnologyDeepSeek V3.2-Speciale | TipRanks - DeepSeek | $13.00 → $12.00−7.7% | Hold | +16.8% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI OpenAI BiotechnologyOpenAI 5.2 | TipRanks - OpenAI | $13.50 → $12.00−11.1% | Hold | +16.8% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI Anthropic BiotechnologyAnthropic Opus-4.6 | TipRanks - Anthropic | $13.00 → $12.00−7.7% | Hold | +16.8% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI Google BiotechnologyGemini 3.1Pro | TipRanks - Google | $13.00 → $11.50−11.5% | Hold | +12.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| AI PerPlexity BiotechnologyPerPlexity SonarPro | TipRanks - PerPlexity | $13.00 → $11.50−11.5% | Hold | +12.0% | Reiterated | 13.10.26on TipRanks 01:06 | — | |
| Mark Massaro★★★★★★★★★★#2635 · hits 40% · avg +5.7% | BTIG | $5.00 | Sell | −51.3% | Reiterated | 04.09.26on TipRanks 07:30 | +0.4%next day +0.4% · 5 days +2.1% | ↗ |
| Jared Haase★★★★★★★★★★#1700 · hits 89% · avg +24.8% | William Blair | — | Sell | — | Reiterated | 13.08.26on TipRanks 17:05 | −6.0%next day +2.4% · 5 days +10.4% | ↗ |
| Unknown Analyst | Bank of America Securities | — | Sell | — | Reiterated | 07.11.25on TipRanks 21:30 | −3.6%next day −3.8% · 5 days −9.0% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Ginkgo Bioworks Holdings
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $7.00 at a price of $12.83 (−45.4%); now: $8.00 at $10.27 (−22.1%).
PriceAverage targetTop analysts’ target
Recommendation trend · top analysts
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 1 | 1 | 1 | 0 | 0 | 0 |
| Hold | 0 | 0 | 0 | 1 | 1 | 2 |
| Sell | 2 | 1 | 1 | 2 | 3 | 3 |
Earnings and sales forecast
Next report: 16.11.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $-0.68 (from $-0.86 to $-0.50). Last quarter: $-0.75.
Sales
Next quarter’s sales estimate — $22M (from $20M to $23M). Last quarter: $20M.
Best top-analyst consensus in the sector · Healthcare
About Ginkgo Bioworks Holdings
- CEO: Jason Kelly
- Employees: 485
- 27 Drydock Avenue, Boston, MA, 02210, US
- www.ginkgo.bio
Ginkgo Bioworks Holdings, Inc., together with its subsidiaries, develops a platform for cell engineering in the United States. It operates through the Cell Engineering and Biosecurity segments. The company offers cell engineering research and development solutions, as well as cell engineering tools comprising functional genomics, antibody developability, and small molecule developability, artificial intelligence models, and reconfigurable automation cart systems on its platform for use in the research, development, and commercialization of engineered organisms and derived products. It also provides biomonitoring and bioinformatics support services through Canopy, which generates genomic data from strategically positioned nodes through biomonitoring programs; and Horizon, a digital surveillance, analytics, and insights platform that detects and monitors biothreats. In addition, the company offers genetic medicine R&D, protein engineering, bioprocess development, crop nutrition and protection solutions, and plant trait optimization. The company serves pharmaceutical and biotechnology, agriculture, industrial and environment, food and nutrition, consumer and technology, and government and defense industries. Ginkgo Bioworks Holdings, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
Data from the stock’s TipRanks forecast page, read 194 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗